Alendronate for the prevention of bone loss in patients on inhaled steroid therapy
Publication in refereed journal


引用次數
替代計量分析
.

其它資訊
摘要One hundred women on inhaled steroid therapy (dose range from 800 to < 1600 mug per day) were randomized to receive 10 mg of oral alendronate or placebo (with 500 mg of calcium in the form of daily calcium carbonate). Bone mineral density (BMD) was measured at baseline, 6 months, and 12 months. The percentage changes in BMD were - 0.80 % in the placebo group and 2.99 % in the alendronate group at the spine (p < 0.001 by analysis of covariance [ANCOVA]), and were -0.51 % in the placebo group and 0.97 % in the alendronate group at the femoral neck (p < 0.05 by ANCOVA). Five patients in the alendronate-treated group, and a similar number of patients in the placebo group, complained of mild gastric discomfort. We conclude that women on inhaled steroid therapy were at risk of accelerated bone loss, which could be prevented by a daily dose of 10 mg of alendronate. (C) 2001 by Elsevier Science Inc. All rights reserved.
著者Lau EMC, Woo J, Chan YH, Li M
期刊名稱BONE
出版年份2001
月份12
日期1
卷號29
期次6
出版社ELSEVIER SCIENCE INC
頁次506 - 510
國際標準期刊號8756-3282
電子國際標準期刊號1873-2763
語言英式英語
關鍵詞alendronate; bisphosphonates; inhaled steroids; osteoporosis
Web of Science 學科類別Endocrinology & Metabolism; ENDOCRINOLOGY & METABOLISM

上次更新時間 2020-08-08 於 02:22